Novel approaches to treatment of locally advanced rectal cancer
A. A. Kachmazov,
L. V. Bolotina,
A. L. Kornietskaya,
Yu. B. Karagodina,
I. V. Droshneva,
A. A. Fedenko https://doi.org/10.17650/2686-9594-2020-10-3-4-73-83
Abstract
Combination of neoadjuvant chemoradiotherapy with subsequent total mesorectum excision and 6-months of adjuvant chemotherapy remains a standard approach to treatment of locally advanced rectal cancer (T3 or T4 and / or N1–3; M0) for more than 15 years, which is reflected in practical guidelines of most leading oncological societies. However, recent data suggests possibilities of more individualized treatment conceptions with a potential of further improvement of long-term therapy outcomes and patient’s quality of life. In this paper we present review of results of clinical trials which investigated new approaches to treatment of locally advanced rectal cancer.
About the Authors
A. A. Kachmazov
P. A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Center of Radiology, Ministry of Health of Russia
Russian Federation
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284
L. V. Bolotina
P. A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Center of Radiology, Ministry of Health of Russia
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284
A. L. Kornietskaya
P. A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Center of Radiology, Ministry of Health of Russia
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284
Yu. B. Karagodina
P. A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Center of Radiology, Ministry of Health of Russia
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284
I. V. Droshneva
P. A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Center of Radiology, Ministry of Health of Russia
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284
A. A. Fedenko
P. A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Center of Radiology, Ministry of Health of Russia
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284
References
1. Practical guideline for pharmacotherapy of malignant tumors. Ed. by V.M. Moiseenko. Russian Society of Clinical Oncology, 2019. Available at: https://rosoncoweb.ru/standarts/RUSSCO/2019/2019-22.pdf. (In Russ.).
2. NCCN Clinical Practice Guidelines in Oncology – Rectal Cancer. Version 4.2020. National Comprehensive Cancer Network.
3. Glynne-Jones R., Wyrwicz L., Tiret E. et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 2017;28(Suppl 4):iv22–iv40. DOI: 10.1093/annonc/mdx224. Available at: https://www.annalsofoncology.org/article/S0923-7534(19)42152-2/abstract.
4. Clinical guideline for cancer treatment. Ed. by A.D. Kaprin. Russian Association of Oncologists, 2020. Available at: https://oncology-association.ru/files/clinical-guidelines-2020/rak_prjamoj_kishki.pdf. (In Russ.).
5. MacFarlane J.K., Ryall R.D.H., Heald R.J. Mesorectal excision for rectal cancer. The Lancet 1993;341(8843): 457–60. Available at: https://www.sciencedirect.com/science/article/abs/pii/014067369390207W.
6. Lambregts D.M.J., Beets-Tan R.G.H. Optimal imaging staging of rectal cancer. Eur J Cancer Suppl 2013;11(2):38–44. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041181/.
7. Sauer R., Becker H., Hohenbergeret W. et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351(17):1731–40. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa040694.
8. Roh M.S., Colangelo L., O’Connell M.J. et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol Off J Am Soc Clin Oncol 2009;27(31):5124–30. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2773471/.
9. Gérard J.-P., Conroy T., Bonnetain F. et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol Off J Am Soc Clin Oncol 2006;24(28):4620–5. Available at: http://estro.dokeos.com/courses/ESTRORECTAL/document/recommended_articles/24-06_JCO_Gerard_FFCD.pdf.
10. Valentini V., Bonnetain F., Gambacorta M. et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol Off J Am Soc Clin Oncol 2011;29(23):3163–72. Available at: https://www.researchgate.net/profile/Marek_Bebenek/publication/51483716_Nomograms_for_Predicting_Local_Recurrence_Distant_Metastases_and_Overall_Survival_for_Patients_With_Locally_Advanced_Rectal_Cancer_on_the_Basis_of_European_Randomized_Clinical_Trials/links/0a85e53224d63d60e0000000/Nomograms-for-Predicting-Local-Recurrence-Distant-Metastases-and-Overall-Survival-for-Patients-With-Locally-Advanced-Rectal-Cancer-on-the-Basis-of-European-Randomized-Clinical-Trials.pdf.
11. Bujko K., Nowacki M., Nasierowska‐ Guttmejer A. et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006;93(10):1215–23. Available at: https://www.ingentaconnect.com/content/jws/bjs/2006/00000093/00000010/art00007.
12. Latkauskas T., Pauzas H., Gineikieneet I. et al. Initial results of a randomized controlled trial comparing clinical and pathological downstaging of rectal cancer after preoperative short-course radiotherapy or long-term chemoradiotherapy, both with delayed surgery. Colorectal Dis Off J Assoc Coloproctology G.B. Irel 2012;14(3):294–8. Available at: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1463-1318.2011.02815.x.
13. Ngan S.Y., Bryan B., Goldstein D. et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol Off J Am Soc Clin Oncol 2012;30(31): 3827–33. Available at: https://www.researchgate.net/profile/Stephen_Ackland/publication/231176339_Randomized_Trial_of_Short-Course_Radiotherapy_Versus_Long-Course_Chemoradiation_Comparing_Rates_of_Local_Recurrence_in_Patients_With_T3_Rectal_Cancer_Trans-Tasman_Radiation_Oncology_Group_Trial_0104/links/57fcdef008aed4ab46fe6730/Randomized-Trial-of-Short-Course-Radiotherapy-Versus-Long-Course-Chemoradiation-Comparing-Rates-of-Local-Recurrence-in-Patients-With-T3-Rectal-Cancer-Trans-Tasman-Radiation-Oncology-Group-Trial-0104.pdf.
14. Francois Y., Nemoz C., Baullieux J. et al. Influence of the interval between preopera tive radiation therapy and surgery on down-staging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol Off J Am Soc Clin Oncol 1999;17(8):2396. Available at: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.1010.4888&rep=rep1&type=pdf.
15. Lefevre J.H., Mineur L., Kotti S. et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol Off J Am Soc Clin Oncol 2016;34(31):3773–80. Available at: https://ascopubs.org/doi/full/10.1200/JCO.2016.67.6049.
16. Raymond E., Chaney S., Taamma A., Cvitkovic E. et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol Off J Eur Soc Med Oncol 1998;9(10):1053–71. Available at: https://www.sciencedirect.com/science/article/pii/S0923753419482045.
17. Grothey A., Sargent D., Goldberg R. et al. Survival of patients with advanced colo rec tal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22(7):1209–14. Available at: https://ascopubs.org/doi/full/10.1200/JCO.2004.11.037.
18. Goldberg R.M., Gill S. Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer. Cancer Chemother Pharmacol 2004;54(Suppl 1):S57–64. Available at: https://link.springer.com/article/10.1007/s00280-004-0888-9.
19. Goldberg R.M., Sargent D., Morton R. et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22(1):23–30. Available at: http://www.hayaobio.net/admin/images/file/20141110144845.pdf.
20. De Gramont A., Figer A., Seymour M. et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18(16):2938–47. Available at: https://ascopubs.org/doi/abs/10.1200/jco.2000.18.16.2938.
21. Zhao L., Bai C., Chao Y. et al. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer. Cancer Lett 2011;310(2):134–9. Available at: https://www.sciencedirect.com/science/article/pii/S0304383511003715.
22. Wang J.-P., Вing W.X., Deng Y.H. et al. Preoperative chemoradiotherapy with FOLFOX in low rectal cancer: a multicenter study. Zhonghua Wei Chang Wai Ke Za Zhi Chin J Gastrointest Surg 2008;11(2):116–9. Available at: https://europepmc.org/article/med/18344075.
23. Aschele C., Cionini L., Lonardi S. et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 Randomized Phase III Trial. J Clin Oncol 2011;29(20):2773–80. DOI: 10.1200/JCO.2010.34.4911. Available at: https://ascopubs.org/doi/10.1200/JCO.2010.34.4911.
24. Gérard J.-P., Azria D., Gourgou-Bourgade S. et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol Off J Am Soc Clin Oncol 2010;28(10):1638–44. Available at: https://ascopubs.org/doi/full/10.1200/JCO.2009.25.8376.
25. Gérard J.-P., Azria D., Gourgou-Bourgade S. et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 2012;30(36):4558–65. Available at: https://ascopubs.org/doi/full/10.1200/JCO.2012.42.8771.
26. Allegra C.J., Yothers G., O’Connell M. et al. Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: A Phase III Randomized Clinical Trial. J Natl Cancer Inst 2015;107(11). Available at: https://academic.oup.com/jnci/article/107/11/djv248/2457689.
27. Schmoll H.-J., Haustermans K., Price T. et al. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis. J Clin Oncol 2014; 32(15 Suppl):3501. Available at: https://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.3501.
28. Roedel C., Becker H., Fietkau R. et al. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: First results of the German CAO/ARO/AIO-04 randomized phase III trial. J Clin Oncol 2011;29(18 Suppl): LBA3505. Available at: https://ascopubs.org/doi/abs/10.1200/jco.2011.29.18_suppl.lba3505.
29. Rödel C., Graeven U., Fietkau R. et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2015;16(8):979–89. Available at: https://www.sciencedirect.com/science/article/pii/S147020451500159X.
30. Zheng J., Feng X., Huet W. et al. Systematic review and meta-analysis of preoperative chemoradiotherapy with or without oxaliplatin in locally advanced rectal cancer. Medicine (Baltimore) 2017;96(13):e6487. DOI: 10.1097/MD.0000000000006487. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380275/.
31. De Felice F., Benevento I., Magnante A. et al. Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis: Oxaliplatin in neoadjuvant treatment for rectal cancer. BMC Cancer 2017;17(1):325. Available at: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3323-4.
32. Tournigand C., Andre T., Achille E. et al. FOLFIRI followed by FOLFOX6 or the re verse sequence in advanced colorec tal cancer: a randomized GERCOR study. J Clin Oncol Off J Am Soc Clin Oncol 2004;22(2):229–37. Available at: http://mauriciolema.webhost4life.com/rolmm/files/GERCOR.pdf.
33. Klautke G., Küchenmeister U., Foitziket T. al. Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study. Br J Cancer 2006;94(7):976–81. Available at: https://www.nature.com/articles/6603053.
34. Jung M., Shin S., Koom W. et al. A randomized phase 2 study of neoadjuvant chemoradiaton therapy with 5-fluorouracil/leucovorin or irinotecan/S-1 in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2015;93(5):1015–22. Available at: https://www.sciencedirect.com/science/article/pii/S0360301615031946.
35. DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. 10 th edn. Philadelphia: LWW, 2014. 2280 p.
36. Wong S.J., Winter K., Meropol N. et al. RTOG 0247: A randomized phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiation therapy for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2012;82(4):1367–75. Available at: https://ascopubs.org/doi/abs/10.1200/jco.2008.26.15_suppl.4021.
37. Wong S.J., Moughan J., Meropol N. et al. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2015;91(1):116–23. Available at: https://www.sciencedirect.com/science/article/pii/S0360301614041807.
38. Zhu J., Sun X., Liu A. et al. A randomized phase III trial of capecitabine with or without irinotecan driven by UGT1A1 in neoadjuvant chemoradiation of locally advanced rectal cancer (CinClare). J Clin Oncol Am Soc Clin Oncol 2017;35(15 Suppl):TPS3632. Available at: https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.3510.
39. Horisberger K., Treschl A., Mai S. et al. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. Int J Radiat Oncol Biol Phys 2009; 74(5):1487–93. DOI: 10.1016/j.ijrobp.2008.10.014. Available at: https://www.sciencedirect.com/science/article/pii/S0360301608035906.
40. Eisterer W., de Vries A., Ofner D. et al. Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer – a phase II clinical trial. Anticancer Res 2014;34(11): 6767–73. Available at: http://ar.iiarjournals.org/content/34/11/6767.short.
41. Rödel C., Arnold D., Hippet M. al. Phase I–II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preopera tive treatment in rectal cancer. Int J Radiat Oncol Biol Phys 2008;70(4):1081–6. Available at: https://www.sciencedirect.com/science/article/pii/S0360301607037790.
42. De Felice F., Izzo L., Musio D. et al. Clinical predictive factors of pathologic complete response in locally advanced rectal cancer. Oncotarget 2016;7(22):33374–80. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078102/.
43. Kripp M., Horisberger K., Mai S. et al. Does the addition of cetuximab to radiochemotherapy improve outcome of patients with locally advanced rectal cancer? Long-term results from phase II trials. Gastroenterol Res Pract 2015;2015:273489. DOI: 10.1155/2015/273489. Available at: https://www.hindawi.com/journals/grp/2015/273489/.
44. Benevento I., De Felice F., Musio D., Tombolini V. The addition of target therapy to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a review. Chemotherapy 2017;62(5):314–22. Available at: https://www.karger.com/Article/Abstract/476056.
45. Cabebe E.C., Kuo T., Koong A., et al. Phase I trial of preoperative cetuximab in combination with oxaliplatin, capecitabine, and radiation therapy for locally advanced rectal cancer. J Clin Oncol 2008;26(15 Suppl):15019. Available at: https://ascopubs.org/doi/abs/10.1200/jco.2008.26.15_suppl.15019.
46. Pinto C., Fabio F., Maiello E. et al. Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). Ann Oncol Off J Eur Soc Med Oncol 2011;22(11):2424–30. Available at: https://www.sciencedirect.com/science/article/pii/S0923753419377117.
47. Mardjuadi F.I., Carrasco J., Coche J. et al. Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer. Target Oncol 2015;10(3):375–83. Available at: https://link.springer.com/article/10.1007/s11523-014-0342-9.
48. Helbling D., Bodoky G., Gautschi O. et al. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Ann Oncol Off J Eur Soc Med Oncol 2013;24(3):718–25. Available at: https://www.sciencedirect.com/science/article/pii/S0923753419371455.
49. Overgaard J., Horsman M. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996;6(1):10–21. Available at: https://www.sciencedirect.com/science/article/pii/S1053429696800324.
50. Hamming L.C., Slotman B., Verheyul H. et al. The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future. Angiogenesis 2017;20(2):217–32. Available at: https://link.springer.com/content/pdf/10.1007/s10456-017-9546-9.pdf.
51. Dings R.P.M., Loren M., Heun H. et al. Scheduling of radiation with angiogenesis inhibitors anginex and avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res Off J Am Assoc Cancer Res 2007;13(11):3395–402. DOI: 10.1158/1078-0432.CCR-06-2441. Available at: https://clincancerres.aacrjournals.org/content/13/11/3395.short.
52. Lee C.G., Heijn M., di Tomaso E. et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60(19):5565–70. Available at: https://cancerres.aacrjournals.org/content/60/19/5565.short.
53. Willett C.G., Boucher E., di Tomaso E. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10(2):145–7. Available at: https://www.nature.com/articles/nm988.
54. Kleibeuker E.A., Fokas E., Allen P. et al. Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect. Oncotarget 2016;7(47):76613–27. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363534/.
55. Teicher B.A., Dupuis N., Kusomoto T. et al. Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat Oncol Investig 1994;2(6):269–76. Available at: https://onlinelibrary.wiley.com/doi/abs/10.1002/roi.2970020604.
56. Teicher B.A., Holdenn S., Ara G. et al. Influence of an anti-angiogenic treatment on 9L gliosarcoma: Oxygenation and response to cytotoxic therapy. Int J Cancer 1995;61(5):732–7. Available at: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.2910610523.
57. Winkler F., Kozin S., Tong R. et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6(6):553–63. Available at: https://www.sciencedirect.com/science/article/pii/S1535610804003058.
58. Jain R.K. Molecular regulation of vessel maturation. Nat Med 2003;9(6):685–93. Available at: https://www.nature.com/articles/nm0603-685.
59. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706): 58–62. Available at: https://science.sciencemag.org/content/307/5706/58.abstract.
60. Mayr N.A., Yuh W., Magnotta V. et al. Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: a new noninvasive predictive assay. Int J Radiat Oncol Biol Phys 1996;36(3):623–33. Available at: https://www.sciencedirect.com/science/article/pii/S0360301697850900.
61. Shibuya K., Tsushima Y., Horisoko E. et al. Blood flow change quantification in cervical cancer before and during radiation therapy using perfusion CT. J Radiat Res (Tokyo) 2011;52(6):804–11. Available at: https://www.jstage.jst.go.jp/article/jrr/52/6/52_11079/article/-char/ja/.
62. Janssen M.H.M., Aerts H., Kerkelset R. et al. Tumor perfusion increases during hypofractionated short-course radiotherapy in rectal cancer: sequential perfusion-CT findings. Radiother Oncol J Eur Soc Ther Radiol Oncol 2010;94(2):156–60. Available at: https://www.sciencedirect.com/science/article/pii/S0167814009006719.
63. Borg C., Andre T., Mantion G. et al. Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study. Ann Oncol Off J Eur Soc Med Oncol 2014;25(11):2205–10. Available at: https://www.sciencedirect.com/science/article/pii/S0923753419367717.
64. Salazar R., Capdevila J., Laquente B. et al. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. BMC Cancer 2015;(15):60. Available at: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-1053-z.
65. Dellas K., Höhler T., Reese T. et al. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. Radiat Oncol Lond Engl 2013;(8):90. Available at: https://link.springer.com/article/10.1186/1748-717X-8-90.
66. Landry J.C., Feng Y., Prabhu R. et al. Phase II trial of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: 5-year clinical outcomes ECOG-ACRIN Cancer Research Group E3204. The Oncologist 2015;20(6):615–6. DOI: 10.1634/theoncologist.2015-0106. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571787/.
67. Kennecke H., Berry S., Wong R. et al. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial. Eur J Cancer Oxf Engl 2012;48(1):37–45. Available at: https://www.sciencedirect.com/science/article/pii/S0959804911003492.
68. Spigel D.R., Bendell J., McCleod M. et al. Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer. Clin Colorectal Cancer 2012;11(1):45–52. Available at: https://www.sciencedirect.com/science/article/pii/S1533002811000338.
69. Resch G., de Vries A., Ofner D. et al. Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer – a two stage phase II clinical trial. Radiother Oncol J Eur Soc Ther Radiol Oncol 2012;102(1):10–3. Available at: https://www.sciencedirect.com/science/article/pii/S0167814011003197.
70. Czito B.G., Yu D., Mantyh Ch. et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol Off J Am Soc Clin Oncol 2006;24(4):656–62. Available at: https://www.researchgate.net/profile/Christopher_Mantyh/publication/7328246_Increased_Toxicity_With_Gefitinib_Capecitabine_and_Radiation_Therapy_in_Pancreatic_and_Rectal_Cancer_Phase_I_Trial_Results/links/00463533d73eed512c000000/Increased-Toxicity-With-Gefitinib-Capecitabine-and-Radiation-Therapy-in-Pancreatic-and-Rectal-Cancer-Phase-I-Trial-Results.pdf.
71. Michael M., Wong R., Singh Gill S. et al. Phase II trial PD-L1/PD-1 blockade avelumab with chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer: The Ave-Rec trial. J Clin Oncol Am Soc Clin Oncol 2019;37(15 Suppl):TPS3622. DOI: 10.1200/JCO. 2019.37.15_suppl.TPS3622. Available at: https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.TPS3622.
72. Chiang S.-F., Chuang C., Ke T.-W. et al. Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers. Cancer Immunol Immunother 2019;68(2):283–96. Available at: https://link.springer.com/article/10.1007/s00262-018-2275-0.
73. Rödel C., Hofheinz R., Fokas E. Rectal cancer: Neoadjuvant chemoradiotherapy. Best Pract Res Clin Gastroenterol 2016;30(4):629–39. Available at: https://www.sciencedirect.com/science/article/pii/S1521691816300440.
74. Fernandez-Martos C. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. Ann Oncol 2015;26(8):1722–8. Available at: https://www.sciencedirect.com/science/article/pii/S0923753419318514.
75. Cercek A., Goodman K. Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. J Natl Compr Cancer Netw JNCCN 2014; 12(4):513–9. Available at: https://jnccn.org/view/journals/jnccn/12/4/article-p513.xml.
76. Fokas E., Allgäuer M., Polat B. et al. Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J Clin Oncol Am Soc Clin Oncol 2019;37(34):3212–22. Available at: https://ascopubs.org/doi/abs/10.1200/JCO.19.00308.
77. Glynne-Jones R., Chau I. Neoadjuvant therapy before surgical treatment. EJC Suppl 2013;11(2):45–59. Available at: https://www.sciencedirect.com/science/article/pii/S1359634913000335.
78. Habr-Gama A., Perez R.O., Nadalin V. et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004;240(4):711–7; discussion 717–8. DOI: 10.1097/01.sla.0000141194.27992.32. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1356472/.
79. Martens M.H., Maas M., Heijnen L.A. et al. Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer. JNCI J Natl Cancer Inst Oxford Academic 2016;108(12): 171. DOI: 10.1093/jnci/djw171. Available at: https://academic.oup.com/jnci/article/108/12/djw171/2706932.
80. Garcia-Aguilar J., Patil S., Kim J.K. et al. Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial. J Clin Oncol Am Soc Clin Oncol 2020;38(15 Suppl):4008. DOI: 10.1200/JCO.2020.38.15_suppl.4008. Available at: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.4008.
Review
Views:
593
Email this article 